Sildenafil utilization was prospectively evaluated among 153 men with a history of erectile dysfunction (ED)-prescription drug use prior to starting sildenafil and 164 men who were new starters of ED-prescription drugs. Further, some determinants of sildenafil discontinuation were identified. During a median follow-up period of 18 months 45% of all patients discontinued sildenafil treatment, regardless of earlier treatment history. However, patients with a history of drug treatment for ED were nearly eight times as likely to switch or re-start another EDprescription drug after discontinuing sildenafil compared to previously untreated users. Age > 60 y, diabetes medication, nitrate use, and use of incontinence pads (a proxy for disease=surgery in the pelvic region) were associated with an increased likelihood of discontinuing sildenafil. Although the introduction of sildenafil reduced the barrier to seek medical help for erectile problems, sildenafil treatment failure in previously untreated patients results in a high dropout rate from further ED drug treatment of any kind.
Introduction
Erectile dysfunction (ED) is a common problem in elderly men. In The Netherlands, it has been estimated that there are 300 000 men suffering from ED who regard this as bothersome and a threat to their quality of life. 1 Sildenafil was the first systemic oral agent for the treatment of ED. 2 Despite all attention surrounding sildenafil, little is known about usage patterns of this drug in daily clinical practice. The Dutch cohort of sildenafil users was formed to gather information on sildenafil usage patterns in a naturally occurring group of users, as well as to identify and quantify possible unwanted events. The baseline characteristics of the cohort members were described in an earlier publication. 3 In this study, it was found that only a limited proportion of patients in the cohort (6.3%) had a history of using other ED prescription drugs in the year prior to cohort-entry. This finding indicated that the introduction of sildenafil tapped a new, previously untreated population of men suffering from ED. The objective of the current study was to evaluate the pattern of sildenafil use among these patients and to compare sildenafil use with a randomly sampled group of cohort members who had no history of ED-drug treatment in the year prior to cohort-entry. Further, we sought to identify determinants of sildenafil discontinuation.
Patients and methods

Setting
The methods of data collection in the Dutch cohort of sildenafil users have been described earlier. 3 In short, in January 1999 we invited each pharmacy in The Netherlands (n ¼ 1571) to identify prospectively the first 20 sildenafil prescriptions that were filled in the pharmacy, during the ensuing year. We asked the pharmacist to complete and return a registration form that contained questions regarding patient characteristics, sildenafil prescription characteristics, as well as information on current and recent (the year prior to the sildenafil prescription) prescription drug use. Since most patients in the *Correspondence: P Souverein, Department ofNetherlands designate a single pharmacy to fill prescriptions from GPs or medical specialists, dispensing histories provide an essentially complete account of each patient's exposure to prescription drugs over time. 4 Data have been collected on 3477 sildenafil-using patients. A comparison of patient characteristics with data from an external database has indicated that patients in the cohort are representative of sildenafil users in The Netherlands.
Study population
From the base cohort, we identified all patients (n ¼ 195) who were regular clients in the pharmacy where they filled sildenafil and had a dispensing history of using other ED-prescription drugs (phentolamine=papaverine, alprostadil, yohimbine) in the year prior to cohort-entry. From the patients using sildenafil who did not have a dispensing history of ED-prescription drug use (and were regular clients in the pharmacy from which they received sildenafil), an equal number of cohort members were randomly sampled as a reference group.
All pharmacies were sent a letter with the request to return a (anonymized) medication history of these selected patients covering the 12-month-period before cohort-entry and a period of 12 months after cohort-entry. For each patient, prescription drug use was assessed from the medication history supplied by the pharmacy. The first recorded prescription for sildenafil marked cohort entry. We asked the pharmacist whether the patient had been registered in the pharmacy for at least 12 months after cohortentry and, if not, if it was known whether the patient had moved or had died.
Assessment of prescription drug use during follow-up
Sildenafil use. Sildenafil use during follow-up was assessed using information on the number of sildenafil refills during follow-up, the number of tablets dispensed, changes in dose and switching to other ED prescription drugs. Because sildenafil is used only when needed, its utilization can follow an irregular pattern. Based on this pattern, each patient was classified in one of three categories: continued sildenafil, discontinued sildenafil and switched to another ED prescription drug, or discontinued sildenafil and stopped all ED prescription drugs. We assumed sildenafil discontinuation when: (1) there were no refills of sildenafil during the 12 month follow-up; (2) the patient switched to other ED-drug treatment during follow up without returning to sildenafil; or (3) there was a period of 6 months between the last refill date for sildenafil and the end of follow-up, unless the earlier pattern of sildenafil use could explain such a time lag. When the patient showed an irregular usage pattern, we evaluated the average time to refill (adjusted for number of tablets dispensed) to make a judgement on whether the patient (dis)continued. If still no sound decision could be made, the discontinuation status of the patients was classified as unknown.
Determinants of discontinuation. Reasons for patients to discontinue sildenafil may, among others, be related to non-effectiveness of the drug, the occurrence of adverse events, or changes in health status. In this study, the effect of age ( < 60, 60 y), diabetes mellitus (use of insulin or oral hypoglycaemic agents), use of antihypertensive agents (beta blockers, calcium channel blockers, diuretics, or ACE-inhibitors), angina pectoris (use of nitrates), hypercholesterolemia (use of lipid lowering drugs), use of oral anticoagulants, use of low dose acetylsalicylic acid (30 or 80 mg), use of antidepressants, use of drugs indicated for the treatment of benign prostatic hyperplasia (BPH) and use of incontinence pads (as a proxy for disease or surgical procedures in the pelvic region) were evaluated as potential determinants of sildenafil discontinuation.
All information on the use of prescription drugs and=or medical aids (eg incontinence pads, syringes, bandages) was gathered from the patient's dispensing history. We assessed use of prescription drugs in a 6-month period before the first sildenafil prescription, as well as during follow-up. Exposure was classified dichotomously (ever use), and according to the timing of use. Four categories of exposure were defined: no use, use before the first sildenafil prescription only, use after starting sildenafil only, and use both before and after starting sildenafil.
Data analysis
Patients entered the cohort at the date of the first sildenafil prescription in the medication history. The date of sildenafil discontinuation was defined as the last sildenafil prescription date plus the number of tablets dispensed. The follow-up time for each patient was calculated as the number of days between the date of cohort-entry and the time of discontinuation of sildenafil or censoring. Patients with an unknown discontinuation status were excluded from the analysis. Relative risk (RR) estimates for discontinuation of sildenafil and 95% confidence intervals (CI) were calculated using Cox proportional hazards analysis. We compared patients with a background of ED-treatment (ED þ ) to patients not having a history of ED-treatment (ED 7 ).
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Other potential determinants of sildenafil discontinuation were included in a multivariate Cox regression model by stepwise backward elimination, using a P-value of 0.20 for removal. A P-value of 0.20 was chosen, as we did not want to be too restrictive for variable selection given the low numbers in certain subgroups. In a subsequent analysis, we stratified patients who had discontinued sildenafil into those who switched to another ED-drug, and those who stopped ED-drugs totally.
Results
Information could be retrieved on 350 out of 390 patients (89.7%), indicating a satisfactory participation rate by the pharmacies. Thirty-three of these patients were excluded for various reasons (patient unknown in the pharmacy, no follow-up available, patient registered under multiple patient numbers), leaving 317 patients for further evaluation. There were 153 patients with a background of ED prescription drug use before starting sildenafil (ED þ ) and 164 patients who did not (ED 7 ). The characteristics of the study population are shown in Table 1 . The mean age of the patients was 57 y of age in both groups. The proportion of patients aged under 60 was slightly, but not significantly, higher in the ED þ -group (58.8% vs 53.0%). The most frequently used cardiovascular drugs in both groups were antihypertensive drugs, acetylsalicylic acid and lipid lowering drugs. The use of the latter two drug classes was significantly more frequent in the ED þ -group compared to the ED 7 -group. There was no significant difference with respect to the use of nitrates, oral anticoagulants, antidiabetic medication, antidepressants, BPH drugs, and incontinence pads between patients with and without a background of ED-treatment. The characteristics with respect to sildenafil use during follow-up are displayed in Table 2 . The mean duration of follow-up was 18 months in the ED þ -group compared to 17 months in the ED 7 -group (P < 0.05, Student's t-test). The number of prescriptions that were filled was not different between both groups. Dose changes were significantly more frequent among patients with a history of EDtreatment. Further, it was found that over 10% of the patients in this group alternated sildenafil and cavernosal injection therapy. The proportion of patients that discontinued sildenafil treatment was similar in both groups: 47.6% vs 45.4%.
However, there were striking differences between the ED þ -group and the ED 7 -group with respect to the type of discontinuation, as shown in Figure 1a .
Patients with a history of earlier ED-drug treatment were far more likely to switch to another ED-drug (26.6% of all patients, 55.9% of the patients discontinuing sildenafil) compared to patients who had never used ED medication before (2.6% of all patients, 5.8% of the patients discontinuing sildenafil). In Figure 1b , we further stratified by the number of sildenafil prescriptions (one vs more than one prescription). Among patients who filled just a single sildenafil prescription, 93% (n ¼ 39) in the ED 7 -group stopped ED-treatment, compared to 25% of the patients in the ED þ -group (RR 3.71, 95% CI 2.03 -6.81). Switching occurred mainly after one prescription (ED þ -group 75%; ED 7 -group 7%, RR 10.50, 95% CI: 3.47 -31.82). Among patients who filled more than one sildenafil prescription, the proportion of patients stopping ED-drugs was similar for both patients with and without a history of earlier ED drug treatment (20 vs 24%, respectively). Patients filling a second sildenafil prescription were younger, but did not differ significantly In a subsequent analysis discontinuation was stratified according to whether the patient switched (back) to another ED-drug or stopped all ED-drugs. The most interesting findings were obtained for history of earlier drug treatment for ED. Patients with a history of earlier ED-treatment were nearly eight times as likely to switch back to a formerly used ED-product (33.6%) after stopping sildenafil relative to patients who had no background of EDtreatment prior to using sildenafil (4.6%): adjusted RR 7.69 (95% CI: 2.71 -21.8). Stopping ED-drugs was less frequent among patients in the ED þ -group (28.6%) compared with the ED 7 -group 43.9%: adjusted RR 0.48 (95% CI: 0.31 -0.76). There were no major differences between the relative risk estimates for switching and stopping between other determinants of sildenafil discontinuation (data not shown).
Discussion
In the medical literature, community studies on sildenafil utilization are limited. Harrold et al. investigated sildenafil usage among 899 patients during the first 24 weeks of sildenafil availability in a Massachusetts population. 5 They found that 61% of all patients refilled sildenafil within 3 months of the first prescription, and that patients having a history of previous treatment were more likely to fill a second prescription. In our study, which had a longer follow-up period, we found a difference in this respect with 77.1% of patients with a history of ED-drug use and 72.0% of patients without a history of ED-drugs filling at least two prescriptions. Buvat et al reported that none of the 59 patients who had switched from self-injected intracavernosal drugs to Sildenafil (dis)continuation PC Souverein et al oral sildenafil went back to intracavernosal injections during 1 y of follow-up. 6 This result contrasts with our finding that only 53% of patients with a history of prior ED prescription drug use (virtually everyone an injection therapy) continued sildenafil. El-Galley et al found that 43 (52%) out of 82 sildenafil users who had been followed-up for a period of 2 y were still using sildenafil at this time. 7 Their results seem comparable with the observations in this study, although it must be noted that 46% of the patients interviewed at baseline in the El-Galley study were lost to follow-up and results might therefore be biased. Studies on the efficacy of sildenafil have shown that the etiology of ED is a principal determinant of efficacy. 8 -11 In our study, we observed that the proportion of patients that stopped sildenafil treatment was increased for patients aged over 60, but also for patients suffering from diabetes and incontinence. Data from clinical trials report that 56 -63% of patients with concomitant diabetes has improved erections. Persistence of sildenafil treatment among the patients with diabetes in this study was around 40%, which is -not surprisingly -lower than reported in trial populations. For instance, Jones et al found that 40 -50% of patients starting antihypertensive treatment had discontinued after 6 months. 12 Use of incontinence pads was significantly associated with increased discontinuation of sildenafil treatment. This finding was true for both switching ED-drugs and stopping ED-treatment, and may be explained by the fact that ED in combination with (transient) incontinence is known to occur frequently following pelvic trauma and extensive pelvic surgery, such as (non-nervesparing) radical prostatectomy, a condition in which the efficacy of sildenafil is known to be remarkably reduced. 13 -15 Drug-induced ED is common. In particular, antipsychotics, antidepressants and antihypertensive agents have been linked with ED. 16 In this study, we found no effect of stopping antihypertensive drugs on sildenafil discontinuation. This finding is consistent with the statement from Jackson that in general most ED observed in cardiovascular patients is a result from vascular disease and not a side effect of drug therapy. 17 Patients who filled prescriptions for antidepressants prior to the start of sildenafil treatment, and did not refill afterwards had a significantly increased likelihood of discontinuing sildenafil. As both depression and use of antidepressants are associated with ED, stopping antidepressants may indicate the improvement of depressive symptoms, and improved erectile function, making sildenafil administration no longer necessary. Concomitant use of both nitrates and sildenafil is strictly contra-indicated, as sildenafil potentiates the hypotensive effects of nitrates. 18 The observation that nitrate use was a determinant for sildenafil discontinuation is therefore consistent with the perception that co-use between both products should be avoided.
In our baseline study, we concluded that the introduction of sildenafil tapped a new, previously untreated population of patients suffering from ED. 3 A Dutch study on ED and its influence on quality of life and healthcare-seeking behaviour, performed prior to the introduction of sildenafil on the Dutch market, revealed that just 25% of patients with ED consulted their GP, and did so only after an average delay of 13 months. 1 The introduction of oral sildenafil is likely to have lowered the initial barrier to seek help for erectile problems. Treatment guidelines in The Netherlands judge oral sildenafil as the first choice before more invasive forms of therapy. 19 Therefore, it was interesting to observe that 46 of the 164 'new' patients (28.1%) filled just a single prescription, and that 93% of these patients subsequently stopped all drug treatment for ED. McCullough et al found in a study among 654 men that the cumulative probability of achieving intercourse success increased with the number of attempts, and reached a plateau after approximately eight attempts. The authors suggest that to increase the intercourse success rate with sildenafil treatment, physicians should give attention to dose titration and should encourage the patients not to discontinue sildenafil prematurely. 20 Switching to another ED-drug was uncommon in patients with no prior background of ED-treatment and suggests that there is a certain barrier toward more invasive therapies (ie cavernosal injections). An alternative explanation for the high dropout after one sildenafil prescription might be that patients did not have ED and used sildenafil merely as an aphrodisiac to stimulate their sexual life. Such misclassification would have resulted in an overestimation of the dropout rate, in particular in the ED 7 -group. On the other hand, all prescriptions were made by physicians, implying that patients (should) have gone through a medical evaluation. If ED was a psychological problem, sildenafil use could have revived self-confidence making further refills not necessary.
All data in this study originated from the patients' dispensing history in the pharmacy. We did not have access to specific medical information (diagnoses, surgical procedures) for the patients in the cohort. Medical conditions that were associated with a reduced efficacy of sildenafil that could not be identified through pharmacy data could not be detected. Therefore, some level of residual confounding cannot be excluded and is likely. Also, discontinuation of sildenafil was measured indirectly through pharmacy medication data, which, of course, can only show the occurrence or nonoccurrence of refilled prescriptions for sildenafil. The discontinuation date was defined as the date of last recorded prescription plus the number of tablets that were dispensed. As there is no way of determining the actual time of discontinuation, the Sildenafil (dis)continuation PC Souverein et al minimum duration of use after the last prescription was used. Results were not different when using alternative definitions, for instance by taking into account the patients refill pattern. We tried to minimize outcome-misclassification by assessing the pattern of sildenafil use for each patient individually, rather than using a general set of rules. If patients could not be classified on the basis of the data available, the (dis)continuationstatus was classified as unknown. All patients were regular clients in the pharmacy where they filled their sildenafil prescriptions. It is possible that patients refilled sildenafil prescriptions in another pharmacy, and hence were incorrectly classified as having discontinued sildenafil. However, the fact that all patients included in this study filled at least one prescription for sildenafil in their regular pharmacy makes it unlikely that many patients turned to another pharmacy or other source (eg the Internet) for filling of subsequent prescriptions for sildenafil.
In conclusion, in this prospective study of sildenafil use in a Dutch cohort of sildenafil users we found that about 45% of all patients starting sildenafil discontinued its use during a median follow-up period of 1.5 y. We identified several (markers for) medical conditions that were associated with an increased likelihood of sildenafil discontinuation in this group of patients. The study, performed in a real-life setting, confirms expectations from efficacy data in clinical trials that persistence with sildenafil differs between patients with different comorbidity, but also shows that the proportion of patients continuing treatment is lower than reported in (extensions) of controlled trial populations. Further, we have shown that although the availability of sildenafil has reduced the barrier for patients to seek medical help for erectile problems, sildenafil treatment failure in previously untreated patients has a much higher rate of dropout from further drug treatment for ED, than in patients who have previously been treated for ED.
